Humoral immune responses to the second dose of a COVID-19 mRNA vaccine in cancer patients undergoing treatment.

ABSTRACT: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak in 2020 led to the immediate development of vaccines to combat SARS-CoV-2 infections and coronavirus disease 2019 (COVID-19). First-generation (2020-2021) COVID-19 vaccines demonstrated high immunogenicity and efficacy, successfully reducing hospitalization, disease severity and COVID-19 related deaths. However, the initial clinical trials for these vaccines focused on overall healthy individuals, and generally excluded high risk populations, such as people with cancer. The SARS-CoV-2 VaccinE Response, Immunological eFfects and safetY in patients with Cancer (VERIFY-C) study formed a unique cohort in early 2021, to capture the initial immune response to BNT162b2 mRNA (Pfizer) vaccination in people with cancer, with o

SUBMITTER: Dang CM 

PROVIDER: S-EPMC12530482 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature